Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.49 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.49 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21241492 | 0.82 | HTR2C (0.52) | PDK1PDK2PDK3PDK4HTR2C | |
| SCHEMBL2438212 | 0.81 | HTR2C (0.48) | PDK1PDK2PDK3PDK4HTR2C | |
| SCHEMBL14248396 | 0.80 | HTR2C (0.50) | PDK1PDK2PDK3PDK4HTR2C | |
| SCHEMBL1643460 | 0.79 | HTR2C (0.51) | PDK1PDK2PDK3PDK4HTR2C | |
| SCHEMBL7714230 | 0.78 | HTR2C (0.48) | PDK1PDK2PDK3PDK4HTR2C | |
| SCHEMBL20656916 | 0.77 | PDK1 (0.49) | PDK1PDK2PDK3PDK4HTR2C | |
| SCHEMBL12293392 | 0.76 | SMN1; SMN2 (0.47) | PDK1PDK2PDK3PDK4HTR2C | |
| SCHEMBL28411733 | 0.76 | HTR2C (0.59) | PDK1PDK2PDK3PDK4HTR2C | |
| SCHEMBL25841627 | 0.76 | HTR2C (0.59) | PDK1PDK2PDK3PDK4HTR2C | |
| SCHEMBL8492254 | 0.76 | PDK1 (0.46) | PDK1PDK2PDK3PDK4HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150376-A1 | Novel Sultam Compounds | PFIZER INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150376-A1 | Novel Sultam Compounds | PFIZER INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2012172449-A1 | LACTAMS AS BETA SECRETASE INHIBITORS | PFIZER INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2011125006-A2 | NOVEL SULTAM COMPOUNDS | PFIZER INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011125006-A2 | NOVEL SULTAM COMPOUNDS | PFIZER INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| US-20110224231-A1 | Novel Lactams as Beta Secretase Inhibitors | PFIZER INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224231-A1 | Novel Lactams as Beta Secretase Inhibitors | PFIZER INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224231-A1 | Novel Lactams as Beta Secretase Inhibitors | PFIZER INC. (US) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224231-A1 | Novel Lactams as Beta Secretase Inhibitors | BACE1, BACE2, APH1B | PDK1 3030/4885PDK2 3827/4885PDK3 3723/4885 |
| US-20130150376-A1 | Novel Sultam Compounds | SULT2A1, SULT1A1, SULT1E1 | PDK1 566/4885PDK2 556/4885PDK3 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.